Monitor for enterprise platform contract announcements or revenue guidance in future filings; this benchmark alone does not change the revenue or cash runway outlook.
Price Chart
Executive Summary
MindWalk published a white paper showing its LensAI immunogenicity screening ran 890,634 antibody sequences in under 5 hours on AMD EPYC cloud instances, achieving up to 43% lower cost per sequence versus Intel. The filing is a technical benchmark update with no financial results, new contracts, or guidance — a routine operational milestone for a pre-revenue-stage AI drug discovery company.
Key Facts
- LensAI screened 890,634 antibody sequences in 4 hours 41 minutes on Amazon EC2 Hpc8a instances with AMD EPYC processors.
- Up to 43% lower cost per sequence versus an Intel Xeon configuration on the identical workload.
- Benchmark results are specific to the configurations tested and not representative of all workloads.
- No financial results, revenue, earnings, guidance, new contracts, or capital allocation changes were disclosed.
- The company is a pre-revenue Bio-Native AI firm; the filing is a technical white paper announcement.
Financial Impact
No financial figures disclosed; the filing describes potential cost efficiencies but provides no revenue, margin, or contract data.
Risk Factors
- Benchmark results may not generalize to other workloads or customer deployments.
- No contracted recurring revenue or commercial adoption metrics provided.
- Company remains pre-revenue with reliance on third-party cloud and chip providers.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-427256 |
| Document: hyft-ex99_1.htm | 0001193125-26-427256 |
| Document: 0001193125-26-427256-index-headers.html | 0001193125-26-427256 |
| Document: 0001193125-26-427256-index.html | 0001193125-26-427256 |
| Document: 0001193125-26-427256.txt | 0001193125-26-427256 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.16 | awaiting T+20 | — | $1.15 (−0.86%) |
Oct 21, 2026 5d ago | 6-K | $1.27 | awaiting T+20 | — | $1.15 (−9.45%) |
Oct 14, 2026 12d ago | 6-K | $1.37 | awaiting T+20 | — | $1.15 (−16.06%) |
Oct 6, 2026 20d ago | 6-K | $1.55 | awaiting T+20 | — | $1.15 (−25.81%) |
Sep 21, 2026 5w ago | 6-K | $1.47 $1.32 | ▼ −10.20% | ▼ −9.30% | $1.15 (−21.77%) |
Sep 14, 2026 6w ago | 6-K | $1.16 $1.48 | ▼ −28.14% | ▼ −25.16% | $1.15 (+0.43%) |
Sep 14, 2026 6w ago | 6-K | $1.33 $1.40 | ▲ +5.26% | ▲ +3.00% | $1.15 (−13.53%) |
Jul 31, 2026 12w ago | EFFECT | $1.29 $1.39 | ▲ +7.75% | ▲ +4.76% | $1.15 (−10.85%) |
Jul 6, 2026 16w ago | 6-K | $1.64 $1.29 | ▼ −21.34% | ▼ −20.78% | $1.15 (−29.88%) |
Jul 1, 2026 16w ago | 6-K | $1.62 $1.30 | ▼ −19.75% | ▼ −17.57% | $1.15 (−29.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers